Jacobs Levy Equity Management, Inc Dyne Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$8.53 - $14.28 $1.74 Million - $2.92 Million	-204,542 Reduced 89.39%	24,279 $273,000
Q1 2023 May 15, 2023	SELL	$10.88 - $15.0 $665,551 - $917,580	-61,172 Reduced 21.09%	228,821 $2.64 Million
Q4 2022 Feb 14, 2023	BUY	$9.37 - $13.8 $646,014 - $951,441	68,945 Added 31.19%	289,993 $3.36 Million
Q3 2022 Nov 15, 2022	BUY	$7.2 - $15.17 $1.59 Million - $3.35 Million	221,048 New	221,048 $2.81 Million

209

102M

234K

238K

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $1.22B
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.